The 940th Hostipal of Joint Logistics Support force of Chinese People's Liberation Army, China.
Crit Rev Oncol Hematol. 2024 Dec;204:104495. doi: 10.1016/j.critrevonc.2024.104495. Epub 2024 Sep 3.
Research on the mechanism and application of checkpoint inhibitory receptors in hematologic diseases has progressed rapidly. However, in the treatment of relapserefractory (R/R) hematologic malignancies and anti-programmed cell death protein 1 (PD-1), patients who are resistant to anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) are in urgent need of alternative therapeutic targets. T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) has a broad prospect as an inhibitory receptor like PD-1, but its more specific mechanism of action and application in hematologic diseases still need to be further studied. In this review, we discuss the mechanism of TIGIT pathway, combined effects with other immune checkpoints, immune-related therapy, the impact of TIGIT on hematopoietic stem cell transplantation (HSCT) and the tumor microenvironment (TME) provides a potential therapeutic target for hematologic malignancies.
在血液病中，关于检查点抑制受体的机制和应用的研究进展迅速。然而，在治疗复发/难治性（R/R）血液恶性肿瘤和抗程序性细胞死亡蛋白 1（PD-1）中，对抗细胞毒性 T 淋巴细胞相关抗原 4（CTLA-4）耐药的患者急需替代治疗靶点。T 细胞免疫受体与免疫球蛋白和 ITIM 结构域（TIGIT）作为一种抑制性受体，与 PD-1 具有广阔的前景，但它在血液病中的更具体作用机制和应用仍需要进一步研究。在这篇综述中，我们讨论了 TIGIT 通路的机制，与其他免疫检查点的联合作用，免疫相关治疗，TIGIT 对造血干细胞移植（HSCT）和肿瘤微环境（TME）的影响，为血液恶性肿瘤提供了一个潜在的治疗靶点。
